Biological Predictors of Alzheimer's Disease Treatment.
- Author:
Soo Hyun JOO
1
;
Jeejin IM
;
Chang Uk LEE
Author Information
1. Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. jihan@catholic.ac.kr
- Publication Type:Review
- Keywords:
Alzheimer's disease;
Biomarker;
Amyloid beta;
Acetylcholinesterase inhibitor
- MeSH:
Acetylcholinesterase;
Alzheimer Disease*;
Amyloid beta-Peptides;
Apolipoproteins;
Apolipoproteins E;
Biomarkers;
Cerebrospinal Fluid;
Cholinesterase Inhibitors;
Diagnosis;
Genotype;
Humans;
Lipoproteins;
Plasma
- From:Journal of the Korean Society of Biological Psychiatry
2014;21(4):115-117
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Variety of biomarkers that are related to the Alzheimer's disease and its diagnosis and progress have been found. However, research lacks in predicting the reaction of the treatment. In addition, there is no definite treatment reaction to the disease but rather it is varied. The purpose of this review article is to study the research of the biomarkers that are able to predict the treatment reaction. There was a research that illustrated a relationship between plasma amyloid beta peptide, cerebrospinal fluid tau, neuroanatomical biomarkers and acetylcholinesterase inhibitors. Polymorphisms in genes of the cholinergic markers AChE, BuChE, ChAT and PON-1 were found to be associated with better clinical response to acetylcholinesterase inhibitors. Many pharmacogenetic studies have been conducted to evaluate the impact of the lipoprotein apolipoprotein E (APOE) genotype on treatment response to acetylcholinesterase inhibitor. However, there is no significant influence of the APOE genotypes on treatment response. Further research is needed to find other predictors of treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
